Institute Of Cancer Research: Royal Cancer Hospital (The)

England

UEI
KXJBJJGTZTU3
CAGE
KCQE1
Primary NAICS
Not on record
SAM.gov registration
Active through

Company facts

Self-certified in SAM.gov
  • Non-Profit Organization
  • Educational Institution
  • State Controlled Institution of Higher Learning
Entity structure
International Organization
SAM.gov registration date
Physical address
Institute of Cancer Research, 123 Old Brompton Rd, South Kensington, London SW7 3RP, UK
Website
icr.ac.uk
Founded
1909
Employees
1K-5K
Estimated annual revenue
$250M-$500M
Industry
  1. Health Care
  2. Pharmaceuticals, Biotechnology & Life Sciences
  3. Biotechnology
SIC code
87 Engineering & Management Services

Registration and certifications come from SAM.gov and the SBA; company details from public web sources. Updated .

Contract awards

Award Agency Obligated Awarded
Obtaining erspc control database for the reconciliation of the plco and erspc trail results HHSN261201000676P National Cancer Institute (NIH) $17,653
Analysis of the erspc control database for the reconciliation of the plco and erspc trail results using cisnets models. HHSN261200900598P National Cancer Institute (NIH) $51,588

Grant awards

Award Agency Obligated Awarded
Targeting myeloid chemotaxis to improve clinical outcomes from radioligand therapy in advanced prostate cancer HT9425261E220 Defense Health Agency $1,283,746
BAK-loss lethal prostate cancer: uncovering therapeutic vulnerabilities to deliver new treatments and improve… HT94252510839 Defense Health Agency $749,996
Enhancing efficacy of BH3 mimetics to induce apoptosis in lethal prostate cancer HT94252410452 Defense Health Agency $299,999
Harnessing ECD cleavage of ALK for immunotherapy against neuroblastoma HT94252410440 Defense Health Agency $1,833,330
Dissecting the interplay of molecular and spatial architectures with clinical states in prostate cancer HT94252410416 Defense Health Agency $499,999

Latest 5 listed here. See the rest on GovTribe.

Grant subawards

Prime recipient Prime award Amount Awarded
Weill Medical College Of Cornell University Dr. Anna Wilkins, Project Leader (10% effort or 1.2 CM) I am Project Leader for the MCT at the Royal Marsden/Institute of Cancer Research. Our MCT will be… U54CA274291 $396,390
University Of Southern California Leveraging whole-exome sequence data from diverse biobanks and cohorts to study rare coding variation in prostate cancer R01CA276826 $30,000
University Of Southern California Leveraging whole-exome sequence data from diverse biobanks and cohorts to study rare coding variation in prostate cancer R01CA276826 $37,155
The Washington University Statement of work and deliverables Dr Doran has a longstanding history of collaboration with the XNAT team, is a regular participant on the XNAT Discussion… U24CA258483 $0
The Washington University Statement of work and deliverables Dr Doran has a longstanding history of collaboration with the XNAT team, is a regular participant on the XNAT Discussion… U24CA258483 $125,628

Similar vendors

Vendor Location Primary NAICS
The Wistar Institute Of Anatomy And Biology UEI DW1XZMGNFBL4 Philadelphia, PA 541715 Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
Ecog-Acrin Medical Research Foundation, Inc. UEI SKG7TLUN8JH6 Philadelphia, PA 541714 Research and Development in Biotechnology (except Nanobiotechnology)
Beckman Research Institute Of The City Of Hope UEI NPH1VN32EWN5 Duarte, CA 813212 Voluntary Health Organizations
Dfci UEI DPMGH9MG1X67 Boston, MA 622310 Specialty (except Psychiatric and Substance Abuse) Hospitals
Health Research At Roswell Park UEI YDWAYVVQHNK5 Buffalo, NY 541715 Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)

See more similar vendors on GovTribe

About the company

Written by GovTribe AI ·

Institute Of Cancer Research: Royal Cancer Hospital (The), a United Kingdom-based nonprofit research organization, operates as a federal grant recipient conducting hypothesis-driven biomedical and translational cancer research in oncology therapeutics, biomarker discovery, and immunotherapy development targeting advanced cancers with military health relevance. The Institute acts as a prime recipient on 71% of recent awards and as a sub-recipient on 29%, with all federal funding routed through research grants rather than federal contracts.

The Institute's federal customer base concentrates heavily on defense and military health priorities. Four agencies account for 94% of recent awards: the Defense Health Agency (5 awards, including a $1.28 million Military Medical Research and Development award announced September 2026), the Department of the Army Medical Command (4 awards), the National Institutes of Health National Cancer Institute (6 awards, $36 thousand combined potential value), and the Department of Defense (1 award). The Defense Health Agency and Army Medical Command dominate the Institute's recent grant pipeline, funding prostate cancer therapeutics research, neuroblastoma immunotherapy development, and renal mass biomarker characterization under the Military Medical Research and Development program (CFDA 12.420).

Recent prime grant awards include a $1.28 million Defense Health Agency award (September 2026) for myeloid chemotaxis research to improve radioligand therapy outcomes in advanced prostate cancer through September 2030; a $750 thousand Defense Health Agency award (August 2025) for prostate cancer therapeutic vulnerability research (BAK-LOSS program) through July 2029; a $1.83 million Defense Health Agency award (June 2024) for immunotherapy research targeting neuroblastoma ALK protein cleavage through May 2028; a $500 thousand Defense Health Agency award (June 2024) for molecular and spatial architecture studies in prostate cancer through May 2027; and a $475 thousand Department of the Army Medical Command award (September 2022) for renal mass biomarker characterization through September 2025. The Institute also holds sub-recipient status on grants from Weill Medical College of Cornell University, the University of Southern California, and The Washington University, contributing translational imaging research, whole-exome sequencing analysis for prostate cancer genetics, and medical imaging software development supporting cancer detection AI training.

Activity has accelerated toward defense health funding—one award in 2022, four in 2024, and three in 2025—with the most recent award (September 2026) establishing a four-year performance period. The Institute's work is performed in Great Britain, United Kingdom, with administrative and research oversight at the Royal Marsden and Institute of Cancer Research facilities in London.

Quick answers

Is Institute Of Cancer Research: Royal Cancer Hospital (The) registered in SAM.gov?

Yes. Institute Of Cancer Research: Royal Cancer Hospital (The)'s SAM.gov registration is active through November 14, 2026.

What is Institute Of Cancer Research: Royal Cancer Hospital (The)'s CAGE code?

Institute Of Cancer Research: Royal Cancer Hospital (The)'s CAGE code is KCQE1, and its Unique Entity ID (UEI) is KXJBJJGTZTU3.

What is Institute Of Cancer Research: Royal Cancer Hospital (The)'s most recent federal award?

Institute Of Cancer Research: Royal Cancer Hospital (The)'s most recent federal grant award is Targeting myeloid chemotaxis to improve clinical outcomes from radioligand therapy in advanced prostate cancer (HT9425261E220), from Defense Health Agency, on September 15, 2026.

On GovTribe

See Institute Of Cancer Research: Royal Cancer Hospital (The)'s full federal record

  • Federal contract awards
  • Federal grant awards
  • Funding analysis by agency, NAICS and set-aside
  • Similar vendors
Try for free Login

Find teaming partners on GovTribe